HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease.

AbstractBACKGROUND:
Pimobendan is an important therapy for dogs with myxomatous mitral valve disease (MMVD). The pharmacokinetics are reported in healthy dogs but not in dogs with heart disease.
HYPOTHESIS/OBJECTIVES:
To determine if dog characteristics such as age, breed, body condition score, ACVIM stage of heart disease or biochemical laboratory value alter the pharmacokinetics of orally administered pimobendan and its metabolite in a cohort of dogs with naturally occurring MMVD.
ANIMALS:
Fifty-seven client-owned dogs with MMVD ACVIM Stage B2, C, or D and administered pimobendan to steady state blood concentrations.
METHODS:
Prospective, observational study. Samples were collected using a sparse-sampling protocol at specific intervals after administration of pimobendan. Plasma pimobendan and the active metabolite (O-desmethyl-pimobendan, ODMP) concentrations were determined via high-pressure liquid chromatography and fluorescence detection. Data was analyzed via a population pharmacokinetic approach and nonlinear mixed effects modeling (NLME). Numerous covariates were examined in the NLME model.
RESULTS:
The absorption and elimination half-lives (t1/2 ) were approximately 1.4 and 1 hour for pimobendan and 1.4 and 1.3 hours for ODMP, respectively. Pharmacokinetic parameters were highly variable, especially the values for pimobendan absorption and elimination rate, and absorption rate of ODMP with coefficients of variation of 147.84%, 64.51% and 64.49%, respectively. No covariate evaluated was a significant source of variability.
CONCLUSIONS AND CLINICAL IMPORTANCE:
The pharmacokinetic parameters were highly variable among this group of dogs with MMVD. The variability was not associated with the dog's age, body weight or condition score, stage of heart disease, dose, serum creatinine, or alkaline phosphatase.
AuthorsAnna K McManamey, Teresa C DeFrancesco, Kathryn M Meurs, Mark G Papich
JournalJournal of veterinary internal medicine (J Vet Intern Med) 2023 Nov-Dec Vol. 37 Issue 6 Pg. 2003-2010 ISSN: 1939-1676 [Electronic] United States
PMID37776546 (Publication Type: Observational Study, Veterinary, Journal Article)
Copyright© 2023 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.
Chemical References
  • pimobendan
  • O-desmethylmethoxyphenamine
Topics
  • Humans
  • Dogs
  • Animals
  • Mitral Valve
  • Prospective Studies
  • Heart Valve Diseases (drug therapy, veterinary)
  • Heart Diseases (veterinary)
  • Administration, Oral
  • Dog Diseases (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: